Wells Fargo & Company Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

United Therapeutics (NASDAQ:UTHR) had its target price increased by Wells Fargo & Company from $423.00 to $466.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have an equal weight rating on the biotechnology company’s stock.

UTHR has been the subject of a number of other research reports. UBS Group restated a “buy” rating on shares of United Therapeutics in a research report on Tuesday, February 17th. Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Royal Bank Of Canada boosted their target price on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Finally, HC Wainwright upped their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $533.55.

United Therapeutics Stock Performance

UTHR opened at $503.60 on Thursday. United Therapeutics has a one year low of $266.98 and a one year high of $537.19. The stock has a market capitalization of $21.69 billion, a P/E ratio of 18.05, a price-to-earnings-growth ratio of 2.85 and a beta of 0.85. The business’s 50-day simple moving average is $484.64 and its 200-day simple moving average is $444.51.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the prior year, the firm earned $6.19 EPS. United Therapeutics’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, equities research analysts forecast that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 21,000 shares of United Therapeutics stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $479.99, for a total value of $10,079,790.00. Following the completion of the transaction, the chief financial officer owned 8,142 shares in the company, valued at approximately $3,908,078.58. This trade represents a 72.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $479.91, for a total value of $10,797,975.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 407,954 shares of company stock worth $197,601,528 over the last quarter. 10.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Avoro Capital Advisors LLC boosted its stake in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP raised its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. AQR Capital Management LLC lifted its holdings in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after purchasing an additional 295,221 shares during the last quarter. Invesco Ltd. boosted its position in United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after purchasing an additional 419,588 shares during the period. Finally, Janus Henderson Group PLC boosted its position in United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and reiterated growth ambition — United Therapeutics reported $7.70 EPS (vs. $6.78 expected) and posted record full‑year revenue of $3.18B, supporting upside momentum. Read More.
• Positive Sentiment: Analysts raised price targets materially — H.C. Wainwright (PT to $600, buy), Oppenheimer (PT to $600, outperform) and RBC (PT to $643, outperform) lifted targets after the print, adding potential upside for the stock. Read More. Read More. Read More.
• Positive Sentiment: Management is targeting a ~$4B revenue run‑rate by 2027 tied to upcoming product launches — a clear multi‑year growth thesis that supports analyst optimism. Read More.
• Neutral Sentiment: Bullish options flow around the print — elevated call buying suggests traders were positioning for upside or volatility, which can amplify moves but is not a fundamental change. Read More.
• Neutral Sentiment: Analyst views remain mixed — some firms (BTIG, Morgan Stanley) kept Hold ratings and Morgan Stanley’s $447 target signals caution even as others raise targets, so expect divergent analyst notes ahead. Read More.
• Negative Sentiment: Revenue missed the quarter — $790.2M vs. ~ $814.8M consensus, which prompted earlier weakness and highlights top‑line execution risk. Read More.
• Negative Sentiment: Significant insider selling — the COO sold large blocks (14,440 shares) and a director sold additional lots in February; repeated insider disposals can undermine confidence even if they may be for diversification. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.